Key result
Ibrutinib linked to cardiovascular side effects and potential DOAC interactions.
Key points are not available for this paper at this time.
Design
Other
Answers are grounded in this paper and cite their sources.
May warrant CV monitoring and DOAC interaction checks with ibrutinib; leaves open need for prospective safety studies.
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
Khalid et al. (2018) studied this question. Ibrutinib is associated with cardiovascular side effects and potential interactions with direct oral anticoagulants.
Synapse has enriched 10 related papers. Consider them for comparative context: